Written by:
Dr. Sophie Reynolds
Dr. Sophie Reynolds is a board-certified medical doctor specializing in internal medicine. With over a decade of experience in patient care and medical writing
Alpesib 150 mg Tablet
Please fill in the details below, and we’ll get back to you as soon as possible
Similar Products:
| Image | Product | Manufacturer / Marketed By | Price |
|---|---|---|---|
![]() | LuciAlpe 150 mg Tablet | Lucius Pharma | Ask for Price |
Description
Alpesib 150 mg Tablet contains Alpelisib, a targeted anticancer medicine used to treat certain types of breast cancer. It helps slow tumor growth in patients with PIK3CA-mutated, HR-positive, HER2-negative disease under oncologist supervision.
Benefits
-
Targets tumors with PIK3CA mutation
-
Helps slow cancer growth and spread
-
May improve progression-free survival
-
Oral targeted therapy for convenient dosing
-
Effective after endocrine therapy resistance
Indications and Usage
Alpesib 150 mg Tablet is indicated for:
-
HR-positive, HER2-negative metastatic or advanced breast cancer
-
Confirmed PIK3CA gene mutation
-
Used in combination with fulvestrant
-
For postmenopausal women and adult men after prior endocrine therapy
Diagnosis and treatment must be supervised by an oncologist.
How it Works
Alpelisib selectively inhibits the PI3K-alpha pathway, which is overactive in cancers with PIK3CA mutations. By blocking this signaling, it reduces cancer cell growth, survival, and resistance to hormonal therapy.
Dosage & Administration
-
Typical dose: 150 mg once daily, or as prescribed
-
Taken with food, at the same time each day
-
Swallow tablets whole—do not crush, chew, or break
-
Continue therapy unless disease progression or intolerance occurs
-
Requires routine monitoring of blood sugar, liver function, and skin reactions
-
Do not adjust or stop dose without oncologist approval
Side Effects
Common side effects:
-
High blood sugar (hyperglycemia)
-
Diarrhea
-
Rash or itching
-
Nausea
-
Fatigue
-
Loss of appetite
Serious side effects (seek urgent help):
-
Severe allergic or skin reactions
-
Lung inflammation (pneumonitis)
-
Severe hyperglycemia or ketoacidosis
-
Liver dysfunction
-
Dehydration
Warning and Precaution
-
Not recommended during pregnancy or breastfeeding
-
Use caution in patients with diabetes — high risk of hyperglycemia
-
Monitor liver, kidney, and lung function regularly
-
Avoid alcohol and high-sugar foods if blood sugar increases
-
Inform doctor about all ongoing medications
-
Stop treatment and seek help if severe rash, breathing issues, or extreme fatigue occur
Related Products
Related Posts:
Ruxolitinib Tablets Receive FDA Approval for Hematologic Malignancies
The U.S. Food and Drug Administration (FDA) has approved Ruxolitinib tablets for the treatment of certain hematologic malignancies, marking another
READ MORE »Tovorafenib Approved in Europe for Children with BRAF-Altered Low-Grade Glioma
n Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 14, 2026.n n This marks an important
READ MORE »FDA Approves Vepdegestrant for ER+/HER2–, ESR1-Mutated Breast Cancer: A New Targeted Option
Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 6, 2026. Breast cancer treatment continues to evolve
READ MORE »Only logged in customers who have purchased this product may leave a review.

Reviews
Clear filtersThere are no reviews yet.